Cardiovascular disease and rheumatoid arthritis: an update.
Patients with rheumatoid arthritis (RA) suffer significantly increased cardiovascular (CV) morbidity and mortality, when compared with the general population. Both traditional CV risk factors and high levels of systemic inflammation have been linked to the increased CV risk in RA patients, but significant uncertainty remains regarding the mechanisms through which these factors contribute to CV disease (CVD). In addition, ongoing questions remain regarding how best to identify RA patients at high risk for CVD and what primary and secondary prevention strategies are effective at influencing CV outcome. The present review summarizes recent research in this field.
Division of Rheumatology, David Geffen School of Medicine, UCLA, 1000 Veteran Avenue Room 32-59, Los Angeles, CA 90095-1670, USA. ccharles@mednet.ucla.edu
Christina
C
Charles-Schoeman
D018501:Antirheumatic Agents / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000188:drug therapy / Q000453:epidemiology; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology*; D002318:Cardiovascular Diseases / Q000175:diagnosis / Q000453:epidemiology* / Q000517:prevention & control; D015897:Comorbidity; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000453:epidemiology; D012307:Risk Factors; D013167:Spondylitis, Ankylosing / Q000188:drug therapy / Q000453:epidemiology; D015996:Survival Rate
D018501:Antirheumatic Agents